Patents Assigned to Medical College of Wisconsin Research Foundation
-
Publication number: 20130316944Abstract: The present invention provides a novel CXCL12-?2 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.Type: ApplicationFiled: July 8, 2013Publication date: November 28, 2013Applicants: The Rockefeller University, Medical College of Wisconsin Research FoundationInventors: Brian F. Volkman, Christopher T. Veldkamp, Francis C. Peterson, Thomas Sakmar, Christoph H. Seibert
-
Patent number: 8524670Abstract: The present invention provides a novel CXCL12-?2 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.Type: GrantFiled: November 30, 2010Date of Patent: September 3, 2013Assignees: Medical College of Wisconsin Research Foundation, The Rockefeller UniversityInventors: Brian F. Volkman, Christopher T. Veldkamp, Francis C. Peterson, Thomas Sakmar, Christoph H. Seibert
-
Publication number: 20120172419Abstract: The present invention provides reagents and methods for modulating cone photoreceptor activity, and devices for assessment of cone photoreceptor activity.Type: ApplicationFiled: September 15, 2010Publication date: July 5, 2012Applicants: Medical College of Wisconsin Research Foundation Inc., UNIVERSITY OF WASHINGTONInventors: Jay Neitz, Maureen Neitz, James A. Kuchenbecker
-
Publication number: 20110091410Abstract: The present invention provides a novel CXCL12-?2 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.Type: ApplicationFiled: November 30, 2010Publication date: April 21, 2011Applicant: Medical College of Wisconsin Research FoundationInventors: Brian F. Volkman, Christopher T. Veldkamp, Francis C. Peterson, Thomas Sakmar, Christoph H. Seibert
-
Patent number: 7744590Abstract: A method of treating visual system disease is disclosed. One embodiment comprises the steps of (a) exposing a component of a patient's visual system to light treatment, wherein the light treatment is characterized by wavelength of between 630-1000 nm and power intensity between 10-90 mW/cm2 for a time of 1-3 minutes, and (b) observing restoration of visual system function.Type: GrantFiled: March 27, 2008Date of Patent: June 29, 2010Assignee: Medical College of Wisconsin Research Foundation, Inc.Inventors: Janis T. Eells, Margaret T. T. Wong-Riley, Harry T. Whelan
-
Publication number: 20090305984Abstract: The present invention provides a novel CXCL12-?2 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.Type: ApplicationFiled: February 26, 2009Publication date: December 10, 2009Applicant: Medical College of Wisconsin Research FoundationInventors: Brian F. Volkman, Christopher T. Veldkamp, Francis C. Peterson, Thomas Sakmar, Christoph H. Seibert
-
Publication number: 20090214437Abstract: A system and method for acquiring MR imaging data from a subject includes administering positively-charged nitroxides or gadolinium chelates for in vivo mitochondrial labeling, acquiring MR imaging data from the subject, and reconstructing an image of the subject having enhanced contrast in areas including metabolic and/or mitotic activity.Type: ApplicationFiled: February 23, 2009Publication date: August 27, 2009Applicant: Medical College of Wisconsin Research FoundationInventors: Balaraman Kalyanaraman, Joy Joseph, Kathleen Marie Schmainda, Douglas Edward Prah, Marcos Lopez, Micael J. Hardy
-
Patent number: 6617355Abstract: Asthma is ameliorated, and mild or moderate asthma is prevented from progressing to more severe asthma by administering agents which prevent and/or accommodate for S-nitrosothiol breakdown.Type: GrantFiled: November 4, 1999Date of Patent: September 9, 2003Assignees: The University of Virginia Patent Foundation, Duke University, The Medical College of Wisconsin Research Foundation, Inc.Inventors: Benjamin Gaston, Jonathan S. Stamler, Owen W. Griffith
-
Patent number: 6608110Abstract: Mammals are treated for infections or for conditions associated with pathologically proliferating mammalian cell growth by administration of a manipulator of nitrosative stress to selectively kill or reduce the growth of the microbes or helminths causing the infection or of host cells infected with the microbes or of the pathologically proliferating mammalian cells. Novel agents include &agr;-alkyl-S-alkyl-homocysteine sulfoxmines wherein the &agr;-alkyl contains 2 to 8 carbon atoms, and the S-alkyl contains 1 to 10 carbon atoms. Mammals in need of increased nitrosative stress defenses are treated, e.g., humans at risk for a stroke because of having had a transient ischemic attack, are treated. Treatments to increase nitrosative stress defenses include repeated administrations of low doses of manipulators of nitrosative stress so that the subject treated has increased tolerance to nitrosative stress.Type: GrantFiled: December 13, 2001Date of Patent: August 19, 2003Assignees: Duke University, The Medical College of Wisconsin Research Foundation, Inc.Inventors: Jonathan S. Stamler, Owen W. Griffith
-
Patent number: 6127420Abstract: Selective and irreversible inhibitors of neuronal isoform of nitric oxide synthase catalyzed production of nitric oxide are L-ornithine or L-lysine derivatives having the formula ##STR1## wherein Q is H or (CH.sub.2).sub.r CH.sub.3 where r ranges from 0 to 15, x is 1 or 2, R" is CH.sub.2 or C(H) (CH.sub.2).sub.y CH.sub.3 where y ranges from 0 to 5, R' is CH.sub.2 or C(H) (CH.sub.2).sub.z CH.sub.3 where z ranges from 0 to 5, R is H or (CH.sub.2).sub.s CH.sub.3 where s ranges from 0 to 5, with none or only one of R, R' and R" providing an alkyl substituent on ornithine or lysine moiety, R.sup.III is OH or is an alkoxy group of 1 to 6 carbon atoms or is an amino acid or peptide attached in amide linkage through its free .alpha.-amino group, and R.sup.IV is --H or an acyl group of 1 to 6 carbon atoms or is an amino acid or peptide attached in amide linkage through its free .alpha.-carboxylate group, and mixtures thereof with corresponding D-isomers. A preferred compound is N.sup.Type: GrantFiled: August 7, 1998Date of Patent: October 3, 2000Assignee: The Medical College of Wisconsin Research Foundation, Inc.Inventors: Owen W. Griffith, Ramesh Babu Boga
-
Patent number: 6103722Abstract: Methods and pharmaceutical compositions of matter are disclosed and claimed relating to cardioprotective effect mediated by delta (.delta.) opioid receptor agonists or more specifically delta-1 (.delta..sub.1)-opioid receptor agonists. Further, methods drawn to reducing ischemic damage to organs and tissues having delta (.delta.) opioid receptor agonists or more specifically delta-1 (.delta..sub.1)-opioid receptors are disclosed and claimed. Specifically, methods and pharmaceutical compositions of matter are taught as a means of providing cardioprotective treatment through the administration of delta (.delta.) opioid receptor agonists or more specifically delta-1 (.delta..sub.1)-opioid receptor agonists, such as TAN67(-). Said methods and pharmaceutical compositions are envisioned as a means of reducing myocardial infarction arising from the onset and sequelae of myocardial ischemia.Type: GrantFiled: May 18, 1998Date of Patent: August 15, 2000Assignee: The Medical College of Wisconsin Research Foundation Inc.Inventors: Jo El Schultz, Garrett Gross
-
Patent number: 6057367Abstract: Mammals are treated for infections or for conditions associated with pathologically proliferating mammalian cell growth (for example, certain cancers, restenosis, benign prostatic hypertrophy) by administration of a manipulator of nitrosative stress to selectively kill or reduce the growth of the microbes or helminths causing the infection or of host cells infected with the microbes or of the pathologically proliferating mammalian cells. Novel agents include .alpha.-alkyl-S-alkyl-homocysteine sulfoximines wherein the .alpha.-alkyl contains 2 to 8 carbon atoms, and the S-alkyl-contains 1 to 10 carbon atoms. In another invention herein, mammals in need of increased nitrosative stress defenses are treated, e.g., humans at risk for a stroke because of having had a transient ischemic attack, are treated.Type: GrantFiled: May 7, 1997Date of Patent: May 2, 2000Assignees: Duke University, The Medical College of Wisconsin Research Foundation, Inc.Inventors: Jonathan S. Stamler, Owen W. Griffith
-
Patent number: 5723448Abstract: Administration of argininosuccinate synthetase activity reducing agents, e.g., argininosuccinate synthetase induction blocking agents (e.g., antibiotics that bind to DNA sequences present in the upstream regulatory region of the argininosuccinate synthetase gene, such as mithramycin) and argininosuccinate synthetase inhibitors (e.g., L-citrulline antagonists such as methyl citrulline and L-aspartate antagonists such as D-aspartate) is useful to prevent or treat sepsis or cytokine-induced systemic hypotension, is useful in the treatment of sepsis or cytokine-induced systemic hypotension to restore vascular sensitivity to the effects of .alpha..sub.1 -adrenergic agonists, and is useful to suppress an immune response, e.g., in treating inflammation. In one embodiment, certain argininosuccinate synthetase activity reducing agents are used together with arginine antagonists to treat sepsis or cytokine induced hypotension.Type: GrantFiled: March 20, 1996Date of Patent: March 3, 1998Assignee: The Medical College of Wisconsin Research FoundationInventors: Steven S. Gross, Owen W. Griffith
-
Patent number: 5663364Abstract: Inhibitors of nitric oxide formation from arginine useful for treating hypotension, inflammation, stroke and to restore vascular contractile sensitivity to the effects of .alpha..sub.1 adrenergic agonists are physiologically active compounds including N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties or monoalkyl carbon-substituted N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties, having the formula ##STR1## wherein R is (CH.sub.2).sub.y CH.sub.3 or H, R' is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, and R" is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, with y ranging from 0 to 5, and x is 0 or 1 and wherein none or only one of R, R' and R" provides an alkyl substituent on ornithine or lysine moiety, and wherein Q is a heme binding moiety and/or a sulfur-containing binding moiety and Q' is --NH.sub.2 when there is a double bond between the omega carbon and Q and Q' is .dbd.Type: GrantFiled: October 31, 1995Date of Patent: September 2, 1997Assignee: The Medical College of Wisconsin Research Foundation, Inc.Inventors: Owen W. Griffith, Krishnaswamy Narayanan
-
Patent number: 5545625Abstract: Administration of argininosuccinate synthetase activity reducing agents, e.g., argininosuccinate synthetase induction blocking agents (e.g., antibiotics that bind to DNA sequences present in the upstream regulatory region of the argininosuccinate synthetase gene, such as mithramycin) and argininosuccinate synthetase inhibitors (e.g., L-citrulline antagonists such as methyl citrulline and L-aspartate antagonists such as D-aspartate) is useful to prevent or treat sepsis or cytokine-induced systemic hypotension, is useful in the treatment of sepsis or cytokine-induced systemic hypotension to restore vascular sensitivity to the effects of .alpha..sub.1 -adrenergic agonists, and is useful to suppress an immune response, e.g., in treating inflammation. In one embodiment, certain argininosuccinate synthetase activity reducing agents are used together with arginine antagonists to treat sepsis or cytokine induced hypotension.Type: GrantFiled: December 12, 1994Date of Patent: August 13, 1996Assignee: The Medical College of Wisconsin Research Foundation, Inc.Inventors: Steven S. Gross, Owen W. Griffith
-
Patent number: 5476871Abstract: Inhibitors of nitric oxide formation from arginine useful for treating hypotension, inflammation, stroke and to restore vascular contractile sensitivity to the effects of .alpha..sub.1 -adrenergic agonists are physiologically active compounds including N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties or monoalkyl carbon-substituted N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties, having the formula ##STR1## wherein R is (CH.sub.2).sub.y CH.sub.3 or H, R' is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, and R" is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, with y ranging from 0 to 5, and x is 0 or 1 and wherein none or only one of R, R' and R" provides an alkyl substituent on ornithine or lysine moiety, and wherein Q is alkyl having 1 to 5 carbon atoms, and physiologically acceptable acid addition salts thereof.Type: GrantFiled: September 12, 1994Date of Patent: December 19, 1995Assignee: The Medical College of Wisconsin Research Foundation, Inc.Inventors: Owen W. Griffith, Krishnaswamy Narayanan
-
Patent number: 5464858Abstract: Inhibitors of nitric oxide formation from arginine useful for treating hypotension, inflammation, stroke and to restore vascular contractile sensitivity to the effects of .alpha..sub.1 adrenergic agonists are physiologically active compounds including N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties or monoalkyl carbon-substituted N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties, having the formula ##STR1## wherein R is (CH.sub.2).sub.y CH.sub.3 or H, R' is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, and R" is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, with y ranging from 0 to 5, and x is 0 or 1 and wherein none or only one of R, R' and R" provides an alkyl substituent on ornithine or lysine moiety, and wherein Q is a heme binding moiety and/or a sulfur-containing binding moiety and Q' is --NH.sub.2 when there is a double bond between the omega carbon and Q and Q' is .dbd.Type: GrantFiled: December 12, 1994Date of Patent: November 7, 1995Assignee: The Medical College of Wisconsin Research Foundation, Inc.Inventors: Owen W. Griffith, Krishnaswamy Narayanan
-
Patent number: 5424447Abstract: Inhibitors of nitric oxide formation from arginine useful for treating hypotension, inflammation, stroke and to restore vascular contractile sensitivity to the effects of .alpha..sub.1 adrenergic agonists are physiologically active compounds including N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties or monoalkyl carbon-substituted N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties, having the formula ##STR1## wherein R is (CH.sub.2).sub.y CH.sub.3 or H, R' is CH.sub.2 or C(H) (CH.sub.2).sub.y CH.sub.3, and R" is CH.sub.2 or C(H) (CH.sub.2).sub.y CH.sub.3, with y ranging from 0 to 5, and x is 0 or 1 and wherein none or only one of R, R' and R" provides an alkyl substituent on ornithine or lysine moiety, and wherein Q is a heme binding moiety and/or a sulfur-containing binding moiety and Q' is --NH.sub.2 when there is a double bond between the omega carbon and Q and Q' is .dbd.Type: GrantFiled: July 7, 1993Date of Patent: June 13, 1995Assignee: The Medical College of Wisconsin Research Foundation, Inc.Inventors: Owen W. Griffith, Krishnaswamy Narayanan
-
Patent number: 5418192Abstract: An in vitro method for the production of interferon is set forth. The method involves the culture of monocytes with a new DA15 peptide produced in Daudi cell lines in response to stimulation with interferon gamma.Type: GrantFiled: December 28, 1992Date of Patent: May 23, 1995Assignee: Medical College of Wisconsin Research FoundationInventors: Ernest C. Borden, Michael Recht, Ernest Knight, Jr.
-
Patent number: 5364881Abstract: Inhibitors of nitric oxide formation from arginine useful for treating hypotension, inflammation, stroke and to restore vascular contractile sensitivity to the effects of .alpha..sub.1 -adrenergic agonists are physiologically active compounds including N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties or monoalkyl carbon-substituted N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties, having the formula ##STR1## wherein R is (CH.sub.2).sub.y CH.sub.3 or H, R' is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, and R" is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, with y ranging from 0 to 5, and x is 0 or 1 and wherein none or only one of R, R' and R" provides an alkyl substituent on ornithine or lysine moiety, and wherein Q is alkyl having 1 to 5 carbon atoms, and physiologically acceptable acid addition salts thereof.Type: GrantFiled: November 15, 1993Date of Patent: November 15, 1994Assignee: The Medical College of Wisconsin Research Foundation, Inc.Inventors: Owen W. Griffith, Krishnaswamy Narayanan